Medicover Integrated Clinical Services sp. z o.o
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Balbir-Gurman, Alexandra
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Calendar Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Recruiting
2
300
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
10/24
09/25
Romanowska-Prochnicka, Katarzyna
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Calendar Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Recruiting
2
300
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
10/24
09/25
Jeka, Marta
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Calendar Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Recruiting
2
300
Europe, Japan, US, RoW
HZN-825 BID, Placebo, HZN-825 QD
Amgen
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
10/24
09/25

Download Options